JP Morgan Chase Portfolio holdings
JPMorgan Chase & Co., formed by the 2000 merger of J.P. Morgan & Co. and Chase Manhattan Bank, is a global financial services giant headquartered in New York City, tracing its roots back to 1799 through its predecessor firms. As one of the largest banks in the world, it operates across investment banking, commercial banking, asset management, and consumer banking, managing trillions in assets and serving millions of customers, corporations, and governments. Led by CEO Jamie Dimon since 2005, the firm is renowned for its role in high-profile deals, robust trading operations, and its Chase retail banking network, which includes extensive credit card and mortgage services. Combining a legacy of financial innovation with a dominant market presence, JPMorgan Chase remains a cornerstone of the global economy.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Johnson & Johnson
JNJ
|
+$761M |
| 2 |
iShares iBoxx $ Investment Grade Corporate Bond ETF
LQD
|
+$735M |
| 3 |
Zimmer Biomet
ZBH
|
+$542M |
| 4 |
Amazon
AMZN
|
+$439M |
| 5 |
iShares Core MSCI EAFE ETF
IEFA
|
+$438M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$4.01B |
| 2 |
Vanguard S&P 500 ETF
VOO
|
+$1.11B |
| 3 |
AABA
Altaba Inc
AABA
|
+$699M |
| 4 |
TJX Companies
TJX
|
+$682M |
| 5 |
iShares 20+ Year Treasury Bond ETF
TLT
|
+$647M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 22.01% |
| 2 | Financials | 14.82% |
| 3 | Technology | 12.49% |
| 4 | Healthcare | 9.61% |
| 5 | Consumer Discretionary | 8.75% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
3851
First Trust Consumer Discretionary AlphaDEX Fund
FXD
$245M
| $556K | ﹤0.01% |
13,217
-530
| -4% | -$21.1K |
2013 Q2
18 quarters
|
|
3852
Smith & Nephew
SNN
$11.1B
| $556K | ﹤0.01% |
15,882
-130,235
| -89% | -$4.74M |
2014 Q2
14 quarters
|
|
3853
National Healthcare
NHC
$3.5B
| $552K | ﹤0.01% |
9,052
+4,559
| +101% | +$291K |
2016 Q3
5 quarters
|
|
|
ENTL
3854
DELISTED
Entellus Medical, Inc. Common Stock
ENTL
| $551K | ﹤0.01% |
22,572
+13,103
| +138% | +$252K |
2017 Q2
2 quarters
|
|
3855
iShares MSCI EAFE Growth ETF
EFG
$15.3B
| $549K | ﹤0.01% |
6,789
+1,413
| +26% | +$112K |
2013 Q2
18 quarters
|
|
3856
State Street SPDR Bloomberg International Treasury Bond ETF
BWX
$1.29B
| $544K | ﹤0.01% |
19,140
+76
| +0.4% | +$2.14K |
2013 Q2
18 quarters
|
|
3857
iShares Currency Hedged MSCI Eurozone ETF
HEZU
$564M
| $542K | ﹤0.01% |
18,182
+4,137
| +29% | +$126K |
2014 Q4
12 quarters
|
|
|
AXJV
3858
DELISTED
iShares Edge MSCI Min Vol Asia ex Japan ETF
AXJV
| $540K | ﹤0.01% |
14,852
+57
| +0.4% | +$2.05K |
2017 Q3
1 quarter
|
|
3859
Calumet Specialty Products
CLMT
$4.72B
| $539K | ﹤0.01% |
69,963
+61,125
| +692% | +$510K |
2013 Q2
18 quarters
|
|
3860
Universal Logistics Holdings
ULH
$467M
| $537K | ﹤0.01% |
22,602
+1,602
| +8% | +$35.8K |
2013 Q2
18 quarters
|
|
|
AMRN
3861
Amarin Corp
AMRN
$269M
| $534K | ﹤0.01% |
6,660
+1,378
| +26% | +$95K |
2016 Q3
5 quarters
|
|
3862
First Trust Eurozone AlphaDEX
FEUZ
$113M
| $533K | ﹤0.01% |
12,131
-487
| -4% | -$21K |
2015 Q3
9 quarters
|
|
|
OSG
3863
DELISTED
Overseas Shipholding Group Inc.
OSG
| $533K | ﹤0.01% |
194,546
+73,954
| +61% | +$192K |
2017 Q3
1 quarter
|
|
3864
Babcock & Wilcox
BW
$863M
| $532K | ﹤0.01% |
9,365
-9,286
| -50% | -$421K |
2015 Q3
9 quarters
|
|
3865
iShares US Transportation ETF
IYT
$2.04B
| $530K | ﹤0.01% |
11,060
-197,984
| -95% | -$8.92M |
2013 Q2
18 quarters
|
|
|
SSI
3866
DELISTED
Stage Stores Inc
SSI
| $530K | ﹤0.01% |
315,628
-26,296
| -8% | -$48.5K |
2016 Q4
4 quarters
|
|
3867
State Street SPDR S&P Emerging Markets Dividend ETF
EDIV
$1.16B
| $529K | ﹤0.01% |
16,101
+15,531
| +2,725% | +$480K |
2015 Q4
8 quarters
|
|
3868
Otter Tail
OTTR
$3.71B
| $529K | ﹤0.01% |
11,905
+9,448
| +385% | +$433K |
2016 Q4
4 quarters
|
|
|
LAYN
3869
DELISTED
Layne Christensen Co
LAYN
| $529K | ﹤0.01% |
42,180
-22,975
| -35% | -$294K |
2017 Q2
2 quarters
|
|
3870
PUT
KB Home
KBH
$2.83B
| $527K | ﹤0.01% |
+16,500
| New | +$474K |
2017 Q4
0 quarters
|
|
|
PGNX
3871
DELISTED
Progenics Pharmaceuticals Inc
PGNX
| $527K | ﹤0.01% |
+88,570
| New | +$538K |
2017 Q4
0 quarters
|
|
|
CTWS
3872
DELISTED
Connecticut Water Service Inc
CTWS
| $524K | ﹤0.01% |
9,139
+5,688
| +165% | +$347K |
2015 Q4
8 quarters
|
|
3873
State Street SPDR Portfolio Mortgage Backed Bond ETF
SPMB
$6.82B
| $523K | ﹤0.01% |
20,088
+3,162
| +19% | +$82.7K |
2015 Q2
10 quarters
|
|
|
TLRA
3874
DELISTED
Telaria, Inc.
TLRA
| $522K | ﹤0.01% |
129,447
+53,826
| +71% | +$229K |
2017 Q3
1 quarter
|
|
3875
First Trust US Equity Opportunities ETF
FPX
$1.47B
| $521K | ﹤0.01% |
7,642
-2,080
| -21% | -$138K |
2013 Q3
17 quarters
|
|
Similar funds
JP Morgan Chase's Q4 2017 Portfolio in Review
As of Q4 2017, JP Morgan Chase held 5,783 positions worth $475B, up 4.7% from $453B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
JP Morgan Chase's Q4 2017 filing shows 812 new, 2,513 increased, 1,655 reduced and 342 closed positions. Its largest new stake was Delphi Technologies PLC Ordinary Shares: 2,961,446 shares worth $155M. The largest sale was State Street SPDR S&P 500 ETF Trust, an estimated $4.01B.
By sector, the portfolio is most concentrated in Miscellaneous at 22% of assets, down from 24% a quarter earlier, followed by Financials and Technology.
- JP Morgan Chase's largest Q4 2017 buy was Delphi Technologies PLC Ordinary Shares: 2,961,446 shares worth $155M.
- JP Morgan Chase added most to Johnson & Johnson in Q4 2017, an estimated $761M increase.
- JP Morgan Chase's biggest Q4 2017 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $4.01B.
- JP Morgan Chase fully exited Kite Pharma, Inc. in Q4 2017, selling an estimated $275M.
- JP Morgan Chase's ten largest holdings make up 18% of its $475B portfolio in Q4 2017.
- JP Morgan Chase opened 812 new positions and closed 342 in Q4 2017.
- JP Morgan Chase's portfolio value rose 4.7% quarter-over-quarter to $475B.
Based on JP Morgan Chase's 13F filing for Q4 2017, filed 13 Feb 2018.